Does Semaglutide Improve Insulin Sensitivity — and Is That Why It Works?

The misconception worth correcting first: semaglutide is not insulin, and it doesn't work like metformin

A lot of people searching this question have read something that implied semaglutide is basically an insulin drug, or that it works the same way as metformin by directly sensitising cells to insulin. Neither is accurate. Semaglutide is a GLP-1 receptor agonist, it mimics a gut hormone that your body already produces after eating. Its primary jobs are slowing gastric emptying, reducing appetite, and prompting the pancreas to release insulin only when blood glucose is actually rising. It does not inject insulin. It does not act on insulin receptors directly. If you've been confused by the overlap between diabetes medicine and weight-loss medicine, you're not alone, the NHS notes the distinction carefully on its semaglutide medicines page. Understanding what semaglutide actually is helps make sense of the insulin-sensitivity evidence, which is real but indirect.

What the evidence shows about insulin sensitivity on semaglutide

Clinical trials consistently report improvements in markers of insulin resistance (particularly HOMA-IR (a calculated score based on fasting glucose and insulin levels)) among people taking semaglutide. The STEP 1 trial, published in the New England Journal of Medicine, showed that participants without diabetes lost around 15% of body weight on average over 68 weeks at the 2.4mg maintenance dose, and metabolic markers including insulin resistance improved substantially across the group. The difficulty is attribution. When someone loses 15% of body weight, insulin sensitivity almost always improves, because excess adipose tissue (particularly visceral fat) actively disrupts insulin signalling. Researchers studying GLP-1 medicines have tried to isolate a weight-independent effect by looking at animal models and at very short-duration studies before significant weight loss occurs. There is some signal of a direct hepatic effect (reduced liver fat accumulation improves insulin sensitivity in the liver), and GLP-1 receptors are present on skeletal muscle and adipose tissue, which hints at a direct pathway. The honest scientific position: both routes probably contribute, and the proportions vary between individuals.

Who sees the biggest metabolic shifts, and what that means practically

People who start with the most disrupted insulin metabolism tend to see the largest measurable improvements. That includes people with type 2 diabetes, prediabetes, polycystic ovary syndrome, or significant visceral obesity. If your fasting insulin was high before treatment, it is very likely to fall on semaglutide, partly because you're eating less, partly because the drug smooths out post-meal glucose spikes, and possibly because of the direct receptor effects discussed above. People who start with normal insulin sensitivity are less likely to see dramatic changes in those specific numbers, though they may still benefit from weight loss itself. It's worth knowing that Wegovy (the weight-management formulation of semaglutide) holds separate UK licensing from Ozempic, which is the diabetes formulation. A look at the Wegovy overview explains how the weight-management licence works and which clinical criteria apply. Prescribers at a regulated service like ours consider your metabolic profile as part of the clinical assessment, not just your BMI. You can also read about whether semaglutide is the same as insulin if that distinction still feels unclear after reading this page.

Semaglutide's wider metabolic effects, and a note on prescribing

Beyond insulin sensitivity, semaglutide affects several interconnected metabolic pathways. Reduced appetite leads to lower caloric intake, which reduces hepatic fat and improves liver insulin signalling. Slower gastric emptying blunts the post-meal glucose spike, reducing the demand placed on beta cells each day. Over time, this can allow beta cells to recover some function in people with early type 2 diabetes. The MHRA has also conditionally approved Wegovy for a form of fatty liver disease (MASH) in adults with significant fibrosis (a decision announced in July 2026) which reflects the breadth of its metabolic reach beyond weight alone. None of this means semaglutide is appropriate for everyone with insulin resistance. Prescribing requires clinical assessment. If you're wondering whether treatment could be suitable for you, the starting point is a free consultation with a clinician rather than a supplement aisle, and it may also help to read about whether semaglutide is available over the counter before you explore your options. Some people also notice unexpected sensory changes during treatment, altered smell sensitivity is one that comes up more than you'd expect, and it's worth being aware of. For transparent information about what private treatment involves financially, the Wegovy pricing page sets out what's included. Treatment is a prescription-only medicine, and the right clinical picture (not insulin-sensitivity scores alone) determines whether it's appropriate. Check your eligibility by starting a free consultation with our prescribers at our treatment page.